Global Circular RNA Therapeutics Market Growth (Status and Outlook) 2026-2032
The global Circular RNA Therapeutics market size is predicted to grow from US$ 46.96 million in 2025 to US$ 530 million in 2032; it is expected to grow at a CAGR of 41.0% from 2026 to 2032.
Circular RNA therapeutics represent an emerging RNA treatment modality that uses engineered circular RNA as a direct therapeutic molecule, a protein-expression vehicle, or an in vivo functional regulatory tool. Candidate therapies are generally developed through sequence design, in vitro transcription, RNA circularization, purification, delivery formulation development, and GMP-compliant scale-up manufacturing. Key applications include therapeutic vaccines, protein-expression therapies, in vivo CAR-T, cancer immunotherapy, ischemic tissue repair, genetic diseases, and rare diseases. Upstream inputs mainly include nucleotide raw materials, modified nucleosides, enzymes, plasmid templates, buffers, chromatography media, single-use bioprocessing consumables, lipid nanoparticle materials, viral vectors, analytical reagents, and sterile filling and packaging materials. Downstream customers mainly include innovative biotechnology companies, RNA therapeutic platform developers, vaccine companies, large pharmaceutical companies, CROs, CDMOs, and hospital-based clinical research centers.
The circular RNA therapeutics market remains at an early stage of clinical translation, with industry activity concentrated on platform validation, candidate selection, circularization process optimization, delivery system development, clinical material manufacturing, and safety evaluation. The sector has not yet established stable commercial drug sales, and company value is primarily reflected in patent portfolios, technology platforms, pipeline progress, delivery capabilities, manufacturing scalability, and external partnerships. The number of global companies with clearly disclosed platforms and active development programs remains limited, with the strongest concentrations in the United States and China. European participation is more visible in vector-mediated circular RNA expression systems. Considerable differences remain among direct RNA delivery, lipid nanoparticle delivery, local injection, viral vector delivery, and intracellular circularization approaches, and no single technology architecture has yet become dominant.
Future market development will be driven by the transition from platform proof of concept to integrated validation of clinical efficacy, human safety, and manufacturing feasibility. Early companies have emphasized the potential advantages of circular RNA in molecular stability, expression durability, and programmability, while future competition will increasingly focus on translation efficiency, dose-response relationships, innate immune activation, tissue selectivity, and repeat-dose feasibility. As more candidates enter human trials, the industry is expected to develop product clusters around therapeutic vaccines, in vivo cell reprogramming, localized tissue repair, protein replacement, and genetic disease treatment. Directly delivered circular RNA therapies and vector-mediated expression therapies are likely to coexist, serving different tissues, dosing schedules, and required expression durations.
Market growth is primarily supported by continued innovation in RNA therapeutics, unmet clinical needs, advances in delivery materials, large-pharma collaboration, and accumulating clinical development experience. Compared with linear mRNA, circular RNA may provide a longer protein-expression window in selected applications and potentially reduce the need for frequent dosing. This creates differentiated opportunities in localized sustained expression, long-term protein supplementation, and in vivo immune-cell reprogramming. Oncology, autoimmune disease, ischemic cardiovascular disease, infectious disease, and rare genetic disease are likely to remain key early validation areas. Research agreements, technology licensing, and acquisition activity involving large pharmaceutical companies may provide emerging platform developers with funding, clinical development capabilities, global regulatory resources, and manufacturing support.
The main barriers are the limited maturity of the technology, the absence of established clinical differentiation, and uncertainty regarding industrialization pathways. Although circular RNA may offer improved molecular stability, its actual in vivo translation efficiency, immunogenicity, delivery performance, expression control, and long-term safety require further human evidence. Manufacturing also faces challenges involving circularization yield, removal of residual linear RNA and double-stranded RNA impurities, batch consistency, quality standard development, analytical method validation, and production cost control. Different circularization and delivery approaches may be subject to different regulatory expectations, increasing the complexity of clinical filing and quality control. In the near term, the industry is therefore expected to remain R&D-intensive, with substantial project differentiation, high clinical attrition, and volatile revenue generation.
LPI (LP Information)' newest research report, the ?Circular RNA Therapeutics Industry Forecast? looks at past sales and reviews total world Circular RNA Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected Circular RNA Therapeutics sales for 2026 through 2032. With Circular RNA Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Circular RNA Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Circular RNA Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Circular RNA Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Circular RNA Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Circular RNA Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Circular RNA Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Circular RNA Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Circular RNA therapeutics represent an emerging RNA treatment modality that uses engineered circular RNA as a direct therapeutic molecule, a protein-expression vehicle, or an in vivo functional regulatory tool. Candidate therapies are generally developed through sequence design, in vitro transcription, RNA circularization, purification, delivery formulation development, and GMP-compliant scale-up manufacturing. Key applications include therapeutic vaccines, protein-expression therapies, in vivo CAR-T, cancer immunotherapy, ischemic tissue repair, genetic diseases, and rare diseases. Upstream inputs mainly include nucleotide raw materials, modified nucleosides, enzymes, plasmid templates, buffers, chromatography media, single-use bioprocessing consumables, lipid nanoparticle materials, viral vectors, analytical reagents, and sterile filling and packaging materials. Downstream customers mainly include innovative biotechnology companies, RNA therapeutic platform developers, vaccine companies, large pharmaceutical companies, CROs, CDMOs, and hospital-based clinical research centers.
The circular RNA therapeutics market remains at an early stage of clinical translation, with industry activity concentrated on platform validation, candidate selection, circularization process optimization, delivery system development, clinical material manufacturing, and safety evaluation. The sector has not yet established stable commercial drug sales, and company value is primarily reflected in patent portfolios, technology platforms, pipeline progress, delivery capabilities, manufacturing scalability, and external partnerships. The number of global companies with clearly disclosed platforms and active development programs remains limited, with the strongest concentrations in the United States and China. European participation is more visible in vector-mediated circular RNA expression systems. Considerable differences remain among direct RNA delivery, lipid nanoparticle delivery, local injection, viral vector delivery, and intracellular circularization approaches, and no single technology architecture has yet become dominant.
Future market development will be driven by the transition from platform proof of concept to integrated validation of clinical efficacy, human safety, and manufacturing feasibility. Early companies have emphasized the potential advantages of circular RNA in molecular stability, expression durability, and programmability, while future competition will increasingly focus on translation efficiency, dose-response relationships, innate immune activation, tissue selectivity, and repeat-dose feasibility. As more candidates enter human trials, the industry is expected to develop product clusters around therapeutic vaccines, in vivo cell reprogramming, localized tissue repair, protein replacement, and genetic disease treatment. Directly delivered circular RNA therapies and vector-mediated expression therapies are likely to coexist, serving different tissues, dosing schedules, and required expression durations.
Market growth is primarily supported by continued innovation in RNA therapeutics, unmet clinical needs, advances in delivery materials, large-pharma collaboration, and accumulating clinical development experience. Compared with linear mRNA, circular RNA may provide a longer protein-expression window in selected applications and potentially reduce the need for frequent dosing. This creates differentiated opportunities in localized sustained expression, long-term protein supplementation, and in vivo immune-cell reprogramming. Oncology, autoimmune disease, ischemic cardiovascular disease, infectious disease, and rare genetic disease are likely to remain key early validation areas. Research agreements, technology licensing, and acquisition activity involving large pharmaceutical companies may provide emerging platform developers with funding, clinical development capabilities, global regulatory resources, and manufacturing support.
The main barriers are the limited maturity of the technology, the absence of established clinical differentiation, and uncertainty regarding industrialization pathways. Although circular RNA may offer improved molecular stability, its actual in vivo translation efficiency, immunogenicity, delivery performance, expression control, and long-term safety require further human evidence. Manufacturing also faces challenges involving circularization yield, removal of residual linear RNA and double-stranded RNA impurities, batch consistency, quality standard development, analytical method validation, and production cost control. Different circularization and delivery approaches may be subject to different regulatory expectations, increasing the complexity of clinical filing and quality control. In the near term, the industry is therefore expected to remain R&D-intensive, with substantial project differentiation, high clinical attrition, and volatile revenue generation.
LPI (LP Information)' newest research report, the ?Circular RNA Therapeutics Industry Forecast? looks at past sales and reviews total world Circular RNA Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected Circular RNA Therapeutics sales for 2026 through 2032. With Circular RNA Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Circular RNA Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Circular RNA Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Circular RNA Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Circular RNA Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Circular RNA Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Circular RNA Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Circular RNA Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Protein Expression Therapeutics
- Therapeutic Vaccines
- Other
- Lipid Nanoparticle Delivery
- Local Direct Delivery
- Other
- Intravenous Administration
- Local Injection
- Other
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Orna Therapeutics
- RiboX Therapeutics
- Sail Biomedicines
- Chimerna Therapeutics
- Torque Bio
- Circurna
- Shanghai CirCode Biomed
- Therorna
- Circio Holding
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Circular RNA Therapeutics Market Size (2021-2032)
2.1.2 Circular RNA Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Circular RNA Therapeutics by Country/Region (2021, 2025 & 2032)
2.2 Circular RNA Therapeutics Segment by Type
2.2.1 Protein Expression Therapeutics
2.2.2 Therapeutic Vaccines
2.2.3 Other
2.2.4 Circular RNA Therapeutics Market Size by Type
2.2.4.1 Circular RNA Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Circular RNA Therapeutics Market Size Market Share by Type (2021-2026)
2.3 Circular RNA Therapeutics Segment by Delivery Technology
2.3.1 Lipid Nanoparticle Delivery
2.3.2 Local Direct Delivery
2.3.3 Other
2.3.4 Circular RNA Therapeutics Market Size by Delivery Technology
2.3.4.1 Circular RNA Therapeutics Market Size CAGR by Delivery Technology (2021 VS 2025 VS 2032)
2.3.4.2 Global Circular RNA Therapeutics Market Size Market Share by Delivery Technology (2021-2026)
2.4 Circular RNA Therapeutics Segment by Route of Administration
2.4.1 Intravenous Administration
2.4.2 Local Injection
2.4.3 Other
2.4.4 Circular RNA Therapeutics Market Size by Route of Administration
2.4.4.1 Circular RNA Therapeutics Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.4.4.2 Global Circular RNA Therapeutics Market Size Market Share by Route of Administration (2021-2026)
2.5 Circular RNA Therapeutics Segment by Application
2.5.1 Pharmaceutical and Biotechnology Companies
2.5.2 Research Institutes
2.5.3 Other
2.5.4 Circular RNA Therapeutics Market Size by Application
2.5.4.1 Circular RNA Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Circular RNA Therapeutics Market Size Market Share by Application (2021-2026)
3 CIRCULAR RNA THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Circular RNA Therapeutics Market Size Market Share by Player
3.1.1 Global Circular RNA Therapeutics Revenue by Player (2021-2026)
3.1.2 Global Circular RNA Therapeutics Revenue Market Share by Player (2021-2026)
3.2 Global Circular RNA Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CIRCULAR RNA THERAPEUTICS BY REGION
4.1 Circular RNA Therapeutics Market Size by Region (2021-2026)
4.2 Global Circular RNA Therapeutics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Circular RNA Therapeutics Market Size Growth (2021-2026)
4.4 APAC Circular RNA Therapeutics Market Size Growth (2021-2026)
4.5 Europe Circular RNA Therapeutics Market Size Growth (2021-2026)
4.6 Middle East & Africa Circular RNA Therapeutics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Circular RNA Therapeutics Market Size by Country (2021-2026)
5.2 Americas Circular RNA Therapeutics Market Size by Type (2021-2026)
5.3 Americas Circular RNA Therapeutics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Circular RNA Therapeutics Market Size by Region (2021-2026)
6.2 APAC Circular RNA Therapeutics Market Size by Type (2021-2026)
6.3 APAC Circular RNA Therapeutics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Circular RNA Therapeutics Market Size by Country (2021-2026)
7.2 Europe Circular RNA Therapeutics Market Size by Type (2021-2026)
7.3 Europe Circular RNA Therapeutics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Circular RNA Therapeutics by Region (2021-2026)
8.2 Middle East & Africa Circular RNA Therapeutics Market Size by Type (2021-2026)
8.3 Middle East & Africa Circular RNA Therapeutics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CIRCULAR RNA THERAPEUTICS MARKET FORECAST
10.1 Global Circular RNA Therapeutics Forecast by Region (2027-2032)
10.1.1 Global Circular RNA Therapeutics Forecast by Region (2027-2032)
10.1.2 Americas Circular RNA Therapeutics Forecast
10.1.3 APAC Circular RNA Therapeutics Forecast
10.1.4 Europe Circular RNA Therapeutics Forecast
10.1.5 Middle East & Africa Circular RNA Therapeutics Forecast
10.2 Americas Circular RNA Therapeutics Forecast by Country (2027-2032)
10.2.1 United States Market Circular RNA Therapeutics Forecast
10.2.2 Canada Market Circular RNA Therapeutics Forecast
10.2.3 Mexico Market Circular RNA Therapeutics Forecast
10.2.4 Brazil Market Circular RNA Therapeutics Forecast
10.3 APAC Circular RNA Therapeutics Forecast by Region (2027-2032)
10.3.1 China Circular RNA Therapeutics Market Forecast
10.3.2 Japan Market Circular RNA Therapeutics Forecast
10.3.3 Korea Market Circular RNA Therapeutics Forecast
10.3.4 Southeast Asia Market Circular RNA Therapeutics Forecast
10.3.5 India Market Circular RNA Therapeutics Forecast
10.3.6 Australia Market Circular RNA Therapeutics Forecast
10.4 Europe Circular RNA Therapeutics Forecast by Country (2027-2032)
10.4.1 Germany Market Circular RNA Therapeutics Forecast
10.4.2 France Market Circular RNA Therapeutics Forecast
10.4.3 UK Market Circular RNA Therapeutics Forecast
10.4.4 Italy Market Circular RNA Therapeutics Forecast
10.4.5 Russia Market Circular RNA Therapeutics Forecast
10.5 Middle East & Africa Circular RNA Therapeutics Forecast by Region (2027-2032)
10.5.1 Egypt Market Circular RNA Therapeutics Forecast
10.5.2 South Africa Market Circular RNA Therapeutics Forecast
10.5.3 Israel Market Circular RNA Therapeutics Forecast
10.5.4 Turkey Market Circular RNA Therapeutics Forecast
10.6 Global Circular RNA Therapeutics Forecast by Type (2027-2032)
10.7 Global Circular RNA Therapeutics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Circular RNA Therapeutics Forecast
11 KEY PLAYERS ANALYSIS
11.1 Orna Therapeutics
11.1.1 Orna Therapeutics Company Information
11.1.2 Orna Therapeutics Circular RNA Therapeutics Product Offered
11.1.3 Orna Therapeutics Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Orna Therapeutics Main Business Overview
11.1.5 Orna Therapeutics Latest Developments
11.2 RiboX Therapeutics
11.2.1 RiboX Therapeutics Company Information
11.2.2 RiboX Therapeutics Circular RNA Therapeutics Product Offered
11.2.3 RiboX Therapeutics Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 RiboX Therapeutics Main Business Overview
11.2.5 RiboX Therapeutics Latest Developments
11.3 Sail Biomedicines
11.3.1 Sail Biomedicines Company Information
11.3.2 Sail Biomedicines Circular RNA Therapeutics Product Offered
11.3.3 Sail Biomedicines Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Sail Biomedicines Main Business Overview
11.3.5 Sail Biomedicines Latest Developments
11.4 Chimerna Therapeutics
11.4.1 Chimerna Therapeutics Company Information
11.4.2 Chimerna Therapeutics Circular RNA Therapeutics Product Offered
11.4.3 Chimerna Therapeutics Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Chimerna Therapeutics Main Business Overview
11.4.5 Chimerna Therapeutics Latest Developments
11.5 Torque Bio
11.5.1 Torque Bio Company Information
11.5.2 Torque Bio Circular RNA Therapeutics Product Offered
11.5.3 Torque Bio Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Torque Bio Main Business Overview
11.5.5 Torque Bio Latest Developments
11.6 Circurna
11.6.1 Circurna Company Information
11.6.2 Circurna Circular RNA Therapeutics Product Offered
11.6.3 Circurna Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Circurna Main Business Overview
11.6.5 Circurna Latest Developments
11.7 Shanghai CirCode Biomed
11.7.1 Shanghai CirCode Biomed Company Information
11.7.2 Shanghai CirCode Biomed Circular RNA Therapeutics Product Offered
11.7.3 Shanghai CirCode Biomed Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Shanghai CirCode Biomed Main Business Overview
11.7.5 Shanghai CirCode Biomed Latest Developments
11.8 Therorna
11.8.1 Therorna Company Information
11.8.2 Therorna Circular RNA Therapeutics Product Offered
11.8.3 Therorna Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Therorna Main Business Overview
11.8.5 Therorna Latest Developments
11.9 Circio Holding
11.9.1 Circio Holding Company Information
11.9.2 Circio Holding Circular RNA Therapeutics Product Offered
11.9.3 Circio Holding Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Circio Holding Main Business Overview
11.9.5 Circio Holding Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Circular RNA Therapeutics Market Size (2021-2032)
2.1.2 Circular RNA Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Circular RNA Therapeutics by Country/Region (2021, 2025 & 2032)
2.2 Circular RNA Therapeutics Segment by Type
2.2.1 Protein Expression Therapeutics
2.2.2 Therapeutic Vaccines
2.2.3 Other
2.2.4 Circular RNA Therapeutics Market Size by Type
2.2.4.1 Circular RNA Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Circular RNA Therapeutics Market Size Market Share by Type (2021-2026)
2.3 Circular RNA Therapeutics Segment by Delivery Technology
2.3.1 Lipid Nanoparticle Delivery
2.3.2 Local Direct Delivery
2.3.3 Other
2.3.4 Circular RNA Therapeutics Market Size by Delivery Technology
2.3.4.1 Circular RNA Therapeutics Market Size CAGR by Delivery Technology (2021 VS 2025 VS 2032)
2.3.4.2 Global Circular RNA Therapeutics Market Size Market Share by Delivery Technology (2021-2026)
2.4 Circular RNA Therapeutics Segment by Route of Administration
2.4.1 Intravenous Administration
2.4.2 Local Injection
2.4.3 Other
2.4.4 Circular RNA Therapeutics Market Size by Route of Administration
2.4.4.1 Circular RNA Therapeutics Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.4.4.2 Global Circular RNA Therapeutics Market Size Market Share by Route of Administration (2021-2026)
2.5 Circular RNA Therapeutics Segment by Application
2.5.1 Pharmaceutical and Biotechnology Companies
2.5.2 Research Institutes
2.5.3 Other
2.5.4 Circular RNA Therapeutics Market Size by Application
2.5.4.1 Circular RNA Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Circular RNA Therapeutics Market Size Market Share by Application (2021-2026)
3 CIRCULAR RNA THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Circular RNA Therapeutics Market Size Market Share by Player
3.1.1 Global Circular RNA Therapeutics Revenue by Player (2021-2026)
3.1.2 Global Circular RNA Therapeutics Revenue Market Share by Player (2021-2026)
3.2 Global Circular RNA Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CIRCULAR RNA THERAPEUTICS BY REGION
4.1 Circular RNA Therapeutics Market Size by Region (2021-2026)
4.2 Global Circular RNA Therapeutics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Circular RNA Therapeutics Market Size Growth (2021-2026)
4.4 APAC Circular RNA Therapeutics Market Size Growth (2021-2026)
4.5 Europe Circular RNA Therapeutics Market Size Growth (2021-2026)
4.6 Middle East & Africa Circular RNA Therapeutics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Circular RNA Therapeutics Market Size by Country (2021-2026)
5.2 Americas Circular RNA Therapeutics Market Size by Type (2021-2026)
5.3 Americas Circular RNA Therapeutics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Circular RNA Therapeutics Market Size by Region (2021-2026)
6.2 APAC Circular RNA Therapeutics Market Size by Type (2021-2026)
6.3 APAC Circular RNA Therapeutics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Circular RNA Therapeutics Market Size by Country (2021-2026)
7.2 Europe Circular RNA Therapeutics Market Size by Type (2021-2026)
7.3 Europe Circular RNA Therapeutics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Circular RNA Therapeutics by Region (2021-2026)
8.2 Middle East & Africa Circular RNA Therapeutics Market Size by Type (2021-2026)
8.3 Middle East & Africa Circular RNA Therapeutics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CIRCULAR RNA THERAPEUTICS MARKET FORECAST
10.1 Global Circular RNA Therapeutics Forecast by Region (2027-2032)
10.1.1 Global Circular RNA Therapeutics Forecast by Region (2027-2032)
10.1.2 Americas Circular RNA Therapeutics Forecast
10.1.3 APAC Circular RNA Therapeutics Forecast
10.1.4 Europe Circular RNA Therapeutics Forecast
10.1.5 Middle East & Africa Circular RNA Therapeutics Forecast
10.2 Americas Circular RNA Therapeutics Forecast by Country (2027-2032)
10.2.1 United States Market Circular RNA Therapeutics Forecast
10.2.2 Canada Market Circular RNA Therapeutics Forecast
10.2.3 Mexico Market Circular RNA Therapeutics Forecast
10.2.4 Brazil Market Circular RNA Therapeutics Forecast
10.3 APAC Circular RNA Therapeutics Forecast by Region (2027-2032)
10.3.1 China Circular RNA Therapeutics Market Forecast
10.3.2 Japan Market Circular RNA Therapeutics Forecast
10.3.3 Korea Market Circular RNA Therapeutics Forecast
10.3.4 Southeast Asia Market Circular RNA Therapeutics Forecast
10.3.5 India Market Circular RNA Therapeutics Forecast
10.3.6 Australia Market Circular RNA Therapeutics Forecast
10.4 Europe Circular RNA Therapeutics Forecast by Country (2027-2032)
10.4.1 Germany Market Circular RNA Therapeutics Forecast
10.4.2 France Market Circular RNA Therapeutics Forecast
10.4.3 UK Market Circular RNA Therapeutics Forecast
10.4.4 Italy Market Circular RNA Therapeutics Forecast
10.4.5 Russia Market Circular RNA Therapeutics Forecast
10.5 Middle East & Africa Circular RNA Therapeutics Forecast by Region (2027-2032)
10.5.1 Egypt Market Circular RNA Therapeutics Forecast
10.5.2 South Africa Market Circular RNA Therapeutics Forecast
10.5.3 Israel Market Circular RNA Therapeutics Forecast
10.5.4 Turkey Market Circular RNA Therapeutics Forecast
10.6 Global Circular RNA Therapeutics Forecast by Type (2027-2032)
10.7 Global Circular RNA Therapeutics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Circular RNA Therapeutics Forecast
11 KEY PLAYERS ANALYSIS
11.1 Orna Therapeutics
11.1.1 Orna Therapeutics Company Information
11.1.2 Orna Therapeutics Circular RNA Therapeutics Product Offered
11.1.3 Orna Therapeutics Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Orna Therapeutics Main Business Overview
11.1.5 Orna Therapeutics Latest Developments
11.2 RiboX Therapeutics
11.2.1 RiboX Therapeutics Company Information
11.2.2 RiboX Therapeutics Circular RNA Therapeutics Product Offered
11.2.3 RiboX Therapeutics Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 RiboX Therapeutics Main Business Overview
11.2.5 RiboX Therapeutics Latest Developments
11.3 Sail Biomedicines
11.3.1 Sail Biomedicines Company Information
11.3.2 Sail Biomedicines Circular RNA Therapeutics Product Offered
11.3.3 Sail Biomedicines Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Sail Biomedicines Main Business Overview
11.3.5 Sail Biomedicines Latest Developments
11.4 Chimerna Therapeutics
11.4.1 Chimerna Therapeutics Company Information
11.4.2 Chimerna Therapeutics Circular RNA Therapeutics Product Offered
11.4.3 Chimerna Therapeutics Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Chimerna Therapeutics Main Business Overview
11.4.5 Chimerna Therapeutics Latest Developments
11.5 Torque Bio
11.5.1 Torque Bio Company Information
11.5.2 Torque Bio Circular RNA Therapeutics Product Offered
11.5.3 Torque Bio Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Torque Bio Main Business Overview
11.5.5 Torque Bio Latest Developments
11.6 Circurna
11.6.1 Circurna Company Information
11.6.2 Circurna Circular RNA Therapeutics Product Offered
11.6.3 Circurna Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Circurna Main Business Overview
11.6.5 Circurna Latest Developments
11.7 Shanghai CirCode Biomed
11.7.1 Shanghai CirCode Biomed Company Information
11.7.2 Shanghai CirCode Biomed Circular RNA Therapeutics Product Offered
11.7.3 Shanghai CirCode Biomed Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Shanghai CirCode Biomed Main Business Overview
11.7.5 Shanghai CirCode Biomed Latest Developments
11.8 Therorna
11.8.1 Therorna Company Information
11.8.2 Therorna Circular RNA Therapeutics Product Offered
11.8.3 Therorna Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Therorna Main Business Overview
11.8.5 Therorna Latest Developments
11.9 Circio Holding
11.9.1 Circio Holding Company Information
11.9.2 Circio Holding Circular RNA Therapeutics Product Offered
11.9.3 Circio Holding Circular RNA Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Circio Holding Main Business Overview
11.9.5 Circio Holding Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Circular RNA Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Circular RNA Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Protein Expression Therapeutics
Table 4. Major Players of Therapeutic Vaccines
Table 5. Major Players of Other
Table 6. Circular RNA Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Circular RNA Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Circular RNA Therapeutics Market Size Market Share by Type (2021-2026)
Table 9. Major Players of Lipid Nanoparticle Delivery
Table 10. Major Players of Local Direct Delivery
Table 11. Major Players of Other
Table 12. Circular RNA Therapeutics Market Size CAGR by Delivery Technology (2021 VS 2025 VS 2032) & ($ millions)
Table 13. Global Circular RNA Therapeutics Market Size by Delivery Technology (2021-2026) & ($ millions)
Table 14. Global Circular RNA Therapeutics Market Size Market Share by Delivery Technology (2021-2026)
Table 15. Major Players of Intravenous Administration
Table 16. Major Players of Local Injection
Table 17. Major Players of Other
Table 18. Circular RNA Therapeutics Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 19. Global Circular RNA Therapeutics Market Size by Route of Administration (2021-2026) & ($ millions)
Table 20. Global Circular RNA Therapeutics Market Size Market Share by Route of Administration (2021-2026)
Table 21. Circular RNA Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 22. Global Circular RNA Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 23. Global Circular RNA Therapeutics Market Size Market Share by Application (2021-2026)
Table 24. Global Circular RNA Therapeutics Revenue by Player (2021-2026) & ($ millions)
Table 25. Global Circular RNA Therapeutics Revenue Market Share by Player (2021-2026)
Table 26. Circular RNA Therapeutics Key Players Head office and Products Offered
Table 27. Circular RNA Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 28. New Products and Potential Entrants
Table 29. Mergers & Acquisitions, Expansion
Table 30. Global Circular RNA Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 31. Global Circular RNA Therapeutics Market Size Market Share by Region (2021-2026)
Table 32. Global Circular RNA Therapeutics Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Circular RNA Therapeutics Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Circular RNA Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 35. Americas Circular RNA Therapeutics Market Size Market Share by Country (2021-2026)
Table 36. Americas Circular RNA Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 37. Americas Circular RNA Therapeutics Market Size Market Share by Type (2021-2026)
Table 38. Americas Circular RNA Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 39. Americas Circular RNA Therapeutics Market Size Market Share by Application (2021-2026)
Table 40. APAC Circular RNA Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 41. APAC Circular RNA Therapeutics Market Size Market Share by Region (2021-2026)
Table 42. APAC Circular RNA Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 43. APAC Circular RNA Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 44. Europe Circular RNA Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 45. Europe Circular RNA Therapeutics Market Size Market Share by Country (2021-2026)
Table 46. Europe Circular RNA Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 47. Europe Circular RNA Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 48. Middle East & Africa Circular RNA Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 49. Middle East & Africa Circular RNA Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 50. Middle East & Africa Circular RNA Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 51. Key Market Drivers & Growth Opportunities of Circular RNA Therapeutics
Table 52. Key Market Challenges & Risks of Circular RNA Therapeutics
Table 53. Key Industry Trends of Circular RNA Therapeutics
Table 54. Global Circular RNA Therapeutics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 55. Global Circular RNA Therapeutics Market Size Market Share Forecast by Region (2027-2032)
Table 56. Global Circular RNA Therapeutics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 57. Global Circular RNA Therapeutics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 58. Orna Therapeutics Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 59. Orna Therapeutics Circular RNA Therapeutics Product Offered
Table 60. Orna Therapeutics Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 61. Orna Therapeutics Main Business
Table 62. Orna Therapeutics Latest Developments
Table 63. RiboX Therapeutics Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 64. RiboX Therapeutics Circular RNA Therapeutics Product Offered
Table 65. RiboX Therapeutics Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 66. RiboX Therapeutics Main Business
Table 67. RiboX Therapeutics Latest Developments
Table 68. Sail Biomedicines Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 69. Sail Biomedicines Circular RNA Therapeutics Product Offered
Table 70. Sail Biomedicines Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 71. Sail Biomedicines Main Business
Table 72. Sail Biomedicines Latest Developments
Table 73. Chimerna Therapeutics Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 74. Chimerna Therapeutics Circular RNA Therapeutics Product Offered
Table 75. Chimerna Therapeutics Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 76. Chimerna Therapeutics Main Business
Table 77. Chimerna Therapeutics Latest Developments
Table 78. Torque Bio Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 79. Torque Bio Circular RNA Therapeutics Product Offered
Table 80. Torque Bio Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 81. Torque Bio Main Business
Table 82. Torque Bio Latest Developments
Table 83. Circurna Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 84. Circurna Circular RNA Therapeutics Product Offered
Table 85. Circurna Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 86. Circurna Main Business
Table 87. Circurna Latest Developments
Table 88. Shanghai CirCode Biomed Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 89. Shanghai CirCode Biomed Circular RNA Therapeutics Product Offered
Table 90. Shanghai CirCode Biomed Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 91. Shanghai CirCode Biomed Main Business
Table 92. Shanghai CirCode Biomed Latest Developments
Table 93. Therorna Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 94. Therorna Circular RNA Therapeutics Product Offered
Table 95. Therorna Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 96. Therorna Main Business
Table 97. Therorna Latest Developments
Table 98. Circio Holding Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 99. Circio Holding Circular RNA Therapeutics Product Offered
Table 100. Circio Holding Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 101. Circio Holding Main Business
Table 102. Circio Holding Latest Developments
Table 1. Circular RNA Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Circular RNA Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Protein Expression Therapeutics
Table 4. Major Players of Therapeutic Vaccines
Table 5. Major Players of Other
Table 6. Circular RNA Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Circular RNA Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Circular RNA Therapeutics Market Size Market Share by Type (2021-2026)
Table 9. Major Players of Lipid Nanoparticle Delivery
Table 10. Major Players of Local Direct Delivery
Table 11. Major Players of Other
Table 12. Circular RNA Therapeutics Market Size CAGR by Delivery Technology (2021 VS 2025 VS 2032) & ($ millions)
Table 13. Global Circular RNA Therapeutics Market Size by Delivery Technology (2021-2026) & ($ millions)
Table 14. Global Circular RNA Therapeutics Market Size Market Share by Delivery Technology (2021-2026)
Table 15. Major Players of Intravenous Administration
Table 16. Major Players of Local Injection
Table 17. Major Players of Other
Table 18. Circular RNA Therapeutics Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 19. Global Circular RNA Therapeutics Market Size by Route of Administration (2021-2026) & ($ millions)
Table 20. Global Circular RNA Therapeutics Market Size Market Share by Route of Administration (2021-2026)
Table 21. Circular RNA Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 22. Global Circular RNA Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 23. Global Circular RNA Therapeutics Market Size Market Share by Application (2021-2026)
Table 24. Global Circular RNA Therapeutics Revenue by Player (2021-2026) & ($ millions)
Table 25. Global Circular RNA Therapeutics Revenue Market Share by Player (2021-2026)
Table 26. Circular RNA Therapeutics Key Players Head office and Products Offered
Table 27. Circular RNA Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 28. New Products and Potential Entrants
Table 29. Mergers & Acquisitions, Expansion
Table 30. Global Circular RNA Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 31. Global Circular RNA Therapeutics Market Size Market Share by Region (2021-2026)
Table 32. Global Circular RNA Therapeutics Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Circular RNA Therapeutics Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Circular RNA Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 35. Americas Circular RNA Therapeutics Market Size Market Share by Country (2021-2026)
Table 36. Americas Circular RNA Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 37. Americas Circular RNA Therapeutics Market Size Market Share by Type (2021-2026)
Table 38. Americas Circular RNA Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 39. Americas Circular RNA Therapeutics Market Size Market Share by Application (2021-2026)
Table 40. APAC Circular RNA Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 41. APAC Circular RNA Therapeutics Market Size Market Share by Region (2021-2026)
Table 42. APAC Circular RNA Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 43. APAC Circular RNA Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 44. Europe Circular RNA Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 45. Europe Circular RNA Therapeutics Market Size Market Share by Country (2021-2026)
Table 46. Europe Circular RNA Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 47. Europe Circular RNA Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 48. Middle East & Africa Circular RNA Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 49. Middle East & Africa Circular RNA Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 50. Middle East & Africa Circular RNA Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 51. Key Market Drivers & Growth Opportunities of Circular RNA Therapeutics
Table 52. Key Market Challenges & Risks of Circular RNA Therapeutics
Table 53. Key Industry Trends of Circular RNA Therapeutics
Table 54. Global Circular RNA Therapeutics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 55. Global Circular RNA Therapeutics Market Size Market Share Forecast by Region (2027-2032)
Table 56. Global Circular RNA Therapeutics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 57. Global Circular RNA Therapeutics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 58. Orna Therapeutics Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 59. Orna Therapeutics Circular RNA Therapeutics Product Offered
Table 60. Orna Therapeutics Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 61. Orna Therapeutics Main Business
Table 62. Orna Therapeutics Latest Developments
Table 63. RiboX Therapeutics Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 64. RiboX Therapeutics Circular RNA Therapeutics Product Offered
Table 65. RiboX Therapeutics Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 66. RiboX Therapeutics Main Business
Table 67. RiboX Therapeutics Latest Developments
Table 68. Sail Biomedicines Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 69. Sail Biomedicines Circular RNA Therapeutics Product Offered
Table 70. Sail Biomedicines Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 71. Sail Biomedicines Main Business
Table 72. Sail Biomedicines Latest Developments
Table 73. Chimerna Therapeutics Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 74. Chimerna Therapeutics Circular RNA Therapeutics Product Offered
Table 75. Chimerna Therapeutics Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 76. Chimerna Therapeutics Main Business
Table 77. Chimerna Therapeutics Latest Developments
Table 78. Torque Bio Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 79. Torque Bio Circular RNA Therapeutics Product Offered
Table 80. Torque Bio Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 81. Torque Bio Main Business
Table 82. Torque Bio Latest Developments
Table 83. Circurna Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 84. Circurna Circular RNA Therapeutics Product Offered
Table 85. Circurna Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 86. Circurna Main Business
Table 87. Circurna Latest Developments
Table 88. Shanghai CirCode Biomed Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 89. Shanghai CirCode Biomed Circular RNA Therapeutics Product Offered
Table 90. Shanghai CirCode Biomed Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 91. Shanghai CirCode Biomed Main Business
Table 92. Shanghai CirCode Biomed Latest Developments
Table 93. Therorna Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 94. Therorna Circular RNA Therapeutics Product Offered
Table 95. Therorna Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 96. Therorna Main Business
Table 97. Therorna Latest Developments
Table 98. Circio Holding Details, Company Type, Circular RNA Therapeutics Area Served and Its Competitors
Table 99. Circio Holding Circular RNA Therapeutics Product Offered
Table 100. Circio Holding Circular RNA Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 101. Circio Holding Main Business
Table 102. Circio Holding Latest Developments
LIST OF FIGURES
Figure 1. Circular RNA Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Circular RNA Therapeutics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Circular RNA Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Circular RNA Therapeutics Sales Market Share by Country/Region (2025)
Figure 8. Circular RNA Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Circular RNA Therapeutics Market Size Market Share by Type in 2025
Figure 10. Global Circular RNA Therapeutics Market Size Market Share by Delivery Technology in 2025
Figure 11. Global Circular RNA Therapeutics Market Size Market Share by Route of Administration in 2025
Figure 12. Circular RNA Therapeutics in Pharmaceutical and Biotechnology Companies
Figure 13. Global Circular RNA Therapeutics Market: Pharmaceutical and Biotechnology Companies (2021-2026) & ($ millions)
Figure 14. Circular RNA Therapeutics in Research Institutes
Figure 15. Global Circular RNA Therapeutics Market: Research Institutes (2021-2026) & ($ millions)
Figure 16. Circular RNA Therapeutics in Other
Figure 17. Global Circular RNA Therapeutics Market: Other (2021-2026) & ($ millions)
Figure 18. Global Circular RNA Therapeutics Market Size Market Share by Application in 2025
Figure 19. Global Circular RNA Therapeutics Revenue Market Share by Player in 2025
Figure 20. Global Circular RNA Therapeutics Market Size Market Share by Region (2021-2026)
Figure 21. Americas Circular RNA Therapeutics Market Size 2021-2026 ($ millions)
Figure 22. APAC Circular RNA Therapeutics Market Size 2021-2026 ($ millions)
Figure 23. Europe Circular RNA Therapeutics Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Circular RNA Therapeutics Market Size 2021-2026 ($ millions)
Figure 25. Americas Circular RNA Therapeutics Value Market Share by Country in 2025
Figure 26. United States Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Circular RNA Therapeutics Market Size Market Share by Region in 2025
Figure 31. APAC Circular RNA Therapeutics Market Size Market Share by Type (2021-2026)
Figure 32. APAC Circular RNA Therapeutics Market Size Market Share by Application (2021-2026)
Figure 33. China Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 37. India Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Circular RNA Therapeutics Market Size Market Share by Country in 2025
Figure 40. Europe Circular RNA Therapeutics Market Size Market Share by Type (2021-2026)
Figure 41. Europe Circular RNA Therapeutics Market Size Market Share by Application (2021-2026)
Figure 42. Germany Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 43. France Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Circular RNA Therapeutics Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Circular RNA Therapeutics Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Circular RNA Therapeutics Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 56. APAC Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 57. Europe Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 59. United States Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 60. Canada Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 61. Mexico Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 62. Brazil Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 63. China Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 64. Japan Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 65. Korea Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 67. India Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 68. Australia Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 69. Germany Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 70. France Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 71. UK Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 72. Italy Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 73. Russia Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 74. Egypt Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 75. South Africa Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 76. Israel Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 77. Turkey Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 78. Global Circular RNA Therapeutics Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Circular RNA Therapeutics Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 1. Circular RNA Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Circular RNA Therapeutics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Circular RNA Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Circular RNA Therapeutics Sales Market Share by Country/Region (2025)
Figure 8. Circular RNA Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Circular RNA Therapeutics Market Size Market Share by Type in 2025
Figure 10. Global Circular RNA Therapeutics Market Size Market Share by Delivery Technology in 2025
Figure 11. Global Circular RNA Therapeutics Market Size Market Share by Route of Administration in 2025
Figure 12. Circular RNA Therapeutics in Pharmaceutical and Biotechnology Companies
Figure 13. Global Circular RNA Therapeutics Market: Pharmaceutical and Biotechnology Companies (2021-2026) & ($ millions)
Figure 14. Circular RNA Therapeutics in Research Institutes
Figure 15. Global Circular RNA Therapeutics Market: Research Institutes (2021-2026) & ($ millions)
Figure 16. Circular RNA Therapeutics in Other
Figure 17. Global Circular RNA Therapeutics Market: Other (2021-2026) & ($ millions)
Figure 18. Global Circular RNA Therapeutics Market Size Market Share by Application in 2025
Figure 19. Global Circular RNA Therapeutics Revenue Market Share by Player in 2025
Figure 20. Global Circular RNA Therapeutics Market Size Market Share by Region (2021-2026)
Figure 21. Americas Circular RNA Therapeutics Market Size 2021-2026 ($ millions)
Figure 22. APAC Circular RNA Therapeutics Market Size 2021-2026 ($ millions)
Figure 23. Europe Circular RNA Therapeutics Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Circular RNA Therapeutics Market Size 2021-2026 ($ millions)
Figure 25. Americas Circular RNA Therapeutics Value Market Share by Country in 2025
Figure 26. United States Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Circular RNA Therapeutics Market Size Market Share by Region in 2025
Figure 31. APAC Circular RNA Therapeutics Market Size Market Share by Type (2021-2026)
Figure 32. APAC Circular RNA Therapeutics Market Size Market Share by Application (2021-2026)
Figure 33. China Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 37. India Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Circular RNA Therapeutics Market Size Market Share by Country in 2025
Figure 40. Europe Circular RNA Therapeutics Market Size Market Share by Type (2021-2026)
Figure 41. Europe Circular RNA Therapeutics Market Size Market Share by Application (2021-2026)
Figure 42. Germany Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 43. France Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Circular RNA Therapeutics Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Circular RNA Therapeutics Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Circular RNA Therapeutics Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Circular RNA Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 56. APAC Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 57. Europe Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 59. United States Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 60. Canada Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 61. Mexico Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 62. Brazil Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 63. China Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 64. Japan Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 65. Korea Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 67. India Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 68. Australia Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 69. Germany Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 70. France Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 71. UK Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 72. Italy Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 73. Russia Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 74. Egypt Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 75. South Africa Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 76. Israel Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 77. Turkey Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
Figure 78. Global Circular RNA Therapeutics Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Circular RNA Therapeutics Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Circular RNA Therapeutics Market Size 2027-2032 ($ millions)
